Sana Biotechnology has announced the successful use of fusogen technology to deliver potent in vivo gene editing of human hematopoietic stem cells (HSCs). Published in Nature Biotechnology, the preclinical research highlights systemic delivery in murine models, demonstrating promising precision for bone marrow–based therapies.

Moran Wealth Management LLC has acquired 13,654 shares of CRISPR Therapeutics AG, reflecting the rising market confidence in the groundbreaking gene-editing field. The investment, worth approximately $664,000, highlights a continued uptick in institutional backing for CRISPR’s innovative biotech research.